121 related articles for article (PubMed ID: 20470805)
1. Early developmental alterations in GABAergic protein expression in fragile X knockout mice.
Adusei DC; Pacey LK; Chen D; Hampson DR
Neuropharmacology; 2010 Sep; 59(3):167-71. PubMed ID: 20470805
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.
Curia G; Papouin T; Séguéla P; Avoli M
Cereb Cortex; 2009 Jul; 19(7):1515-20. PubMed ID: 18787232
[TBL] [Abstract][Full Text] [Related]
3. Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.
Kang JY; Chadchankar J; Vien TN; Mighdoll MI; Hyde TM; Mather RJ; Deeb TZ; Pangalos MN; Brandon NJ; Dunlop J; Moss SJ
J Biol Chem; 2017 Apr; 292(16):6621-6632. PubMed ID: 28213518
[TBL] [Abstract][Full Text] [Related]
4. Cysteine-321 of human brain GABA transaminase is involved in intersubunit cross-linking.
Yoon CS; Kim DW; Jang SH; Lee BR; Choi HS; Choi SH; Kim SY; An JJ; Kwon OS; Kang TC; Won MH; Cho SW; Lee KS; Park J; Eum WS; Choi SY
Mol Cells; 2004 Oct; 18(2):214-9. PubMed ID: 15528998
[TBL] [Abstract][Full Text] [Related]
5. GABAB receptor cell-surface export is controlled by an endoplasmic reticulum gatekeeper.
Doly S; Shirvani H; Gäta G; Meye FJ; Emerit MB; Enslen H; Achour L; Pardo-Lopez L; Yang SK; Armand V; Gardette R; Giros B; Gassmann M; Bettler B; Mameli M; Darmon M; Marullo S
Mol Psychiatry; 2016 Apr; 21(4):480-90. PubMed ID: 26033241
[TBL] [Abstract][Full Text] [Related]
6. Stop and go GABA.
Maher BJ; LoTurco JJ
Nat Neurosci; 2009 Jul; 12(7):817-8. PubMed ID: 19554045
[No Abstract] [Full Text] [Related]
7. GABA and glutamate: the Yin and Yang of fragile X.
Tranfaglia MR
Cell Cycle; 2015; 14(16):2559. PubMed ID: 26102499
[No Abstract] [Full Text] [Related]
8. The developmental switch in GABA polarity is delayed in fragile X mice.
He Q; Nomura T; Xu J; Contractor A
J Neurosci; 2014 Jan; 34(2):446-50. PubMed ID: 24403144
[TBL] [Abstract][Full Text] [Related]
9. The translation of translational control by FMRP: therapeutic targets for FXS.
Darnell JC; Klann E
Nat Neurosci; 2013 Nov; 16(11):1530-6. PubMed ID: 23584741
[TBL] [Abstract][Full Text] [Related]
10. Fragile X syndrome: the GABAergic system and circuit dysfunction.
Paluszkiewicz SM; Martin BS; Huntsman MM
Dev Neurosci; 2011; 33(5):349-64. PubMed ID: 21934270
[TBL] [Abstract][Full Text] [Related]
11. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
12. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.
Deidda G; Bozarth IF; Cancedda L
Front Cell Neurosci; 2014; 8():119. PubMed ID: 24904277
[TBL] [Abstract][Full Text] [Related]
13. Disruption of centrifugal inhibition to olfactory bulb granule cells impairs olfactory discrimination.
Nunez-Parra A; Maurer RK; Krahe K; Smith RS; Araneda RC
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14777-82. PubMed ID: 23959889
[TBL] [Abstract][Full Text] [Related]
14. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Dolan BM; Duron SG; Campbell DA; Vollrath B; Shankaranarayana Rao BS; Ko HY; Lin GG; Govindarajan A; Choi SY; Tonegawa S
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5671-6. PubMed ID: 23509247
[TBL] [Abstract][Full Text] [Related]
15. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
[TBL] [Abstract][Full Text] [Related]
16. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.
Olmos-Serrano JL; Paluszkiewicz SM; Martin BS; Kaufmann WE; Corbin JG; Huntsman MM
J Neurosci; 2010 Jul; 30(29):9929-38. PubMed ID: 20660275
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the excitation-inhibition ratio in the Fmr1 KO2 mouse using neuronal oscillation dynamics.
Kat R; Linkenkaer-Hansen K; Koopmans MA; Houtman SJ; Bruining H; Kas MJH
Cereb Cortex; 2024 May; 34(5):. PubMed ID: 38771240
[TBL] [Abstract][Full Text] [Related]
18. Increased Inhibition May Contribute to Maintaining Normal Network Function in the Ventral Hippocampus of a Fmr1-Targeted Transgenic Rat Model of Fragile X Syndrome.
Leontiadis LJ; Trompoukis G; Felemegkas P; Tsotsokou G; Miliou A; Papatheodoropoulos C
Brain Sci; 2023 Nov; 13(11):. PubMed ID: 38002556
[TBL] [Abstract][Full Text] [Related]
19. Neuroanatomical changes of ionotropic glutamatergic and GABAergic receptor densities in male mice modeling idiopathic and syndromic autism spectrum disorder.
Nardi L; Chhabra S; Leukel P; Krueger-Burg D; Sommer CJ; Schmeisser MJ
Front Psychiatry; 2023; 14():1199097. PubMed ID: 37547211
[TBL] [Abstract][Full Text] [Related]
20. Increased body weight in mice with fragile X messenger ribonucleoprotein 1 (Fmr1) gene mutation is associated with hypothalamic dysfunction.
Ruggiero-Ruff RE; Villa PA; Hijleh SA; Avalos B; DiPatrizio NV; Haga-Yamanaka S; Coss D
Sci Rep; 2023 Aug; 13(1):12666. PubMed ID: 37542065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
